Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alba A Brandes

Showing results (81-90 of 178) with videos related to

Pageof 18
Sort By:
Neurology|March 18, 2014
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 yearsAndrés J M Ferreri, Fabio Ciceri, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patientsAlba A Brandes, Enrico Franceschi, Alicia Tosoni, et al.
International Journal of Radiation Oncology, Biology, Physics|October 8, 2003
The treatment of adults with medulloblastoma: a prospective studyAlba A Brandes, Mario Ermani, Pietro Amista, et al.
Anticancer Research|March 10, 2015
The effect of re-operation on survival in patients with recurrent glioblastomaEnrico Franceschi, Marco Bartolotti, Alicia Tosoni, et al.
Journal of Clinical Pathology|August 29, 2015
Contribution of microRNA analysis to characterisation of pancreatic lesions: a reviewMichela Visani, Giorgia Acquaviva, Sirio Fiorino, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2006
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatmentMathilde C M Kouwenhoven, Johan M Kros, Pim J French, et al.
Oncotarget|September 15, 2017
Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II studyAlba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, et al.
Future Oncology (London, England)|May 22, 2020
Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of ItalyAlba A Brandes, Andrea Ardizzoni, Fabrizio Artioli, et al.
Future Oncology (London, England)|May 10, 2018
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?Enrico Franceschi, Giuseppe Lamberti, Michela Visani, et al.
Histopathology|February 17, 2012
Prognostic value of Ki67 index in anaplastic oligodendroglial tumours--a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor GroupMatthias Preusser, Romana Hoeftberger, Adelheid Woehrer, et al.
Pageof 18

Showing results (81-90 of 178) with videos related to

Sort By:
Pageof 18
Neurology|March 18, 2014
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 yearsAndrés J M Ferreri, Fabio Ciceri, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patientsAlba A Brandes, Enrico Franceschi, Alicia Tosoni, et al.
International Journal of Radiation Oncology, Biology, Physics|October 8, 2003
The treatment of adults with medulloblastoma: a prospective studyAlba A Brandes, Mario Ermani, Pietro Amista, et al.
Anticancer Research|March 10, 2015
The effect of re-operation on survival in patients with recurrent glioblastomaEnrico Franceschi, Marco Bartolotti, Alicia Tosoni, et al.
Journal of Clinical Pathology|August 29, 2015
Contribution of microRNA analysis to characterisation of pancreatic lesions: a reviewMichela Visani, Giorgia Acquaviva, Sirio Fiorino, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2006
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatmentMathilde C M Kouwenhoven, Johan M Kros, Pim J French, et al.
Oncotarget|September 15, 2017
Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II studyAlba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, et al.
Future Oncology (London, England)|May 22, 2020
Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of ItalyAlba A Brandes, Andrea Ardizzoni, Fabrizio Artioli, et al.
Future Oncology (London, England)|May 10, 2018
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?Enrico Franceschi, Giuseppe Lamberti, Michela Visani, et al.
Histopathology|February 17, 2012
Prognostic value of Ki67 index in anaplastic oligodendroglial tumours--a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor GroupMatthias Preusser, Romana Hoeftberger, Adelheid Woehrer, et al.
Pageof 18